Catherine Gagnon
Keine laufenden Positionen mehr
Profil
Catherine Gagnon is currently a Director at Katana Biopharma, Inc. She was previously a Director at Ovensa, Inc. and Head of Business Development at Angiochem, Inc. She received a graduate degree from the University of Montréal in 2000.
Ehemalige bekannte Positionen von Catherine Gagnon
Unternehmen | Position | Ende |
---|---|---|
Katana Biopharma, Inc.
Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Direktor/Vorstandsmitglied | - |
Ovensa, Inc.
Ovensa, Inc. Internet Software/ServicesTechnology Services Ovensa, Inc. operates as a preclinical stage biotechnology company. It focuses in oncology and neurodegenerative diseases. The company is headquartered in Aurora, Canada. | Direktor/Vorstandsmitglied | - |
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
Ausbildung von Catherine Gagnon
University of Montréal | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Katana Biopharma, Inc.
Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Health Services |
Ovensa, Inc.
Ovensa, Inc. Internet Software/ServicesTechnology Services Ovensa, Inc. operates as a preclinical stage biotechnology company. It focuses in oncology and neurodegenerative diseases. The company is headquartered in Aurora, Canada. | Technology Services |